Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | TTR | P02766 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | FABP2 | P12104 | 1/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.65 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terofenamate SCHEMBL9856559 | 0.99 | METTL3 (0.81) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL26088 | 0.99 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL29483481 | 0.99 | METTL3 (0.84) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL16760954 | 0.98 | METTL3 (0.79) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL7636015 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL14247884 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL8814628 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL1671593 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL22612217 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A | |
| Terofenamate SCHEMBL15538328 | 0.98 | METTL3 (0.83) | METTL3PTGS2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2230907-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | Theracos, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | METTL3 1972/4885PTGS2 1014/4885MEN1 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.